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ABSTRACT
Objective: The objective of this study was to assess whether antibiotic therapy plus tocolysis given to
women in preterm labor would prolong pregnancy compared with tocolysis alone.
Methods: A randomized, double-blind trial of intravenous mezlocillin and oral erythromycin
therapy vs. placebo was used in addition to tocolysis among women in preterm labor <34 weeks
gestation with intact membranes. Amniocentesis was performed, and chorioamnionic membranes
were examined histologically and cultured for microorganisms after delivery.
Results: Clinical characteristics including gestational age at enrollment, frequency of contrac-
tions, cervical Bishop’s score, and white blood cell count on admission were similar in the 2 groups.
Antibiotic therapy was well tolerated. No significant differences in the interval to delivery, birth
weight, and neonatal outcomes were observed between the 2 groups. Women in the antibiotic group
had a significantly lower incidence of postpartum infections compared with women in the placebo
group. Patients with evidence of upper genital tract infection in either group had a significantly
shorter interval to delivery, lower gestational age at delivery, lowermean birth weight, and increased
neonatal hospitalization time.
Conclusions: Lack of an antibiotic effect on the gestational age at delivery may be due to the low
prevalence of upper genital tract infection among unselected women in preterm labor, to advanced
preterm labor unresponsive to antibiotic therapy, or to an inability ofantibiotics given alone to inhibit
the cytokine response. Further work is needed to identify markers of upper genital tract infection
among women in preterm labor and to evaluate other potential therapeutic interventions.
(C) 1994 Wiley-Liss, Inc.
KE WORS
Antibiotics, prematurity, amniotic fluid infection
reterm birth remains a major unsolved problem
in obstetrics and infection has been suspected to
play a role in some preterm deliveries. Upper gen-
ital tract (amniotic fluid and chorioamnion) infec-
tion has been identified among a higher proportion
ofwomen delivering preterm compared with those
delivering at term. Amniotic fluid (AF) infection
is present in up to 6 women presenting in preterm
labor (PTL) below 28 weeks gestation. Chorio-
amnion infection decreases from a rate of 80% be-
low 26 weeks to approximately 10% at term,
2 and
histologic chorioamnionitis decreases rapidly from
a rate of 55% below 28 weeks gestation to 5% from
29 weeks gestation to term.
3 Thus, the prevalence
of upper genital tract infection and inflammation is
inversely related to gestational age, and infection
appears to contribute to preterm birth in patients
with PTL resistant to tocolysis.
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Despite the strong association between upper
genital tract infection and preterm delivery, a cause-
and-effect relationship between the 2 has not been
established. Evidence of a cause-and-effect rela-
tionship would be strengthened if a reduction of
preterm delivery occurred among infected patients
given antibiotics in a randomized double-blind fash-
ion. To evaluate the potential contribution of infec-
tion to preterm birth, we randomized women in
PTL with intact membranes to antibiotics or pla-
cebo in addition to tocolytic therapy. Attempts were
made to enroll patients at high risk for infection
and to examine the results in the infected vs. the
uninfected group.
SUBJECTS AND METHODS
Women presenting with preterm contractions with
intact membranes between October 1986 and Oc-
tober 1987 were evaluated for eligibility for this
study. We attempted to enroll patients at increased
risk for infection (<34 weeks getation), but with-
out clinical evidence of infection (<38C tempera-
ture), those with no known cause of labor, yet a
high chance of actually being in PTL. To be in-
cluded, women had to be between the ages of 15-45
years, have a singleton gestation without known
maternal uterine or fetal anomalies, an estimated
gestational age <34 weeks, intact membranes, an
admission temperature <38C, contractions occur-
ring at least every 10 min with a documented cervi-
cal change, and a Bishop’s score of at least 4 with at
least cm dilatation or 50% effacement. Women
allergic to penicillin or erythromycin or on anti-
biotics within the previous 7 days, with cervical
dilatation >4 cm, with placenta previa, vaginal
bleeding more than bloody show, coagulation ab-
normalities or placental abruption noted on ultra-
sound, contraindications to tocolytic therapy, or
difficulty in communication were excluded. Dur-
ing the study period, 718 women presented to the
University of Washington Medical Center with
possible PTL and were screened for enrollment.
Six hundred ten patients (85%) were excluded: pa-
tients with gestational age above 34 weeks, 13%;
preterm rupture of membranes, 29%; no labor,
20%; fetal or uterine anomalies, 5%; placenta pre-
via or abruption, 7%; penicillin or erythromycin
allergies, 4%; multiple gestation, 9%; recent anti-
biotic use, 3%; cervix dilated more than 4 cm, 3%;
maternal medical conditions, 3%; temperature
>38C, 1%; and other conditions including non-
English speaking or psychotic, 3%. In addition, 29
women refused participation. Of the remaining 79
women who were eligible for enrollment, 56 were
approached and signed informed consent to partic-
ipate in the study.
All women underwent ultrasound for assessment
of gestational age and fetal health. Women with
adequateAF volume who consented underwent am-
niocentesis for fetal lung maturity studies and mi-
crobiologic cultures. Aliquots of AF were trans-
ported in a syringe to the clinical microbiology
laboratory for routine bacterial culture and trans-
ported immediately to the research microbiology
laboratory or placed into a Port-a-Cul vial (Becton-
Dickinson Co., Inc., Cockeysville, MD) where
100 Ixl ofAF was cultured as previously reported.
Urine was obtained by bladder catheterization for
urinalysis and culture. A speculum examination
was performed to collect vaginal specimens and to
exclude rupture of the fetal membranes. A vaginal
swab was rolled onto a clear glass slide and ob-
served microscopically for a ferning pattern to rule
out ruptured membranes. The pI--I of the vaginal
fluid was determined by pH paper. Vaginal fluid
was also collected on cotton swabs for Gram stain
and transported in Amies transport medium (Med-
ical Media Lab, Boring, OR) for cultures ofgroup
B Streptococcus and Escherichia coli as previously
described.
4 Cervical specimens were obtained on
dacron swabs for Gram smear and inoculated onto
Thayer-Martin media for Neisseria gonorrhoeae cul-
tures and centrifuged onto McCoy cell monolayers
for Chlamydia trachomatis cultures as previously
indicated, s Vaginal and cervical smears were stained
with crystal violet and Gram’s iodine with a saffra-
nin counterstain and evaluated for the presence of
white blood cells (WBCs) and bacterial vaginosis
according to published criteria.
6 Bishop’s score was
determined by digital examination of the cervix.
After obtaining vaginal AF, urine, and cervical
specimens for culture, we randomly assigned the
women in a blinded fashion to either of 2 groups:
1) mezlocillin, 3 g intravenously (IV) every 6 h,
and erythromycin ethylsuccinate, 333 mg orally
every 8 h; or 2) identical placebos of each. The
antibiotic regimen was chosen to inhibit the most
common microorganisms isolated from AF and the
chorioamnion isolates at our hospital, including
anaerobic and facultative bacteria and Ureaplasma
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urealyticum. 1’2’7 IV therapy was continued for 5
days and oral therapy for 10 days. Tocolytic ther-
apy was administered to all women. The choice of
tocolytics was at the discretion of the resident and
attending physician staff and included IV ritodrine
or magnesium sulfate, intramuscular ritodrine,
and/or oral indomethacin. Women whose PTL had
initially been stopped on parenteral tocolytic ther-
apy received oral terbutaline or ritodrine until de-
livery or 36 completed weeks gestation. Be-
thamethasone in standard doses was administered at
the discretion of the attending and resident physi-
cian staff. Women at less than 34 weeks gestation
with recurrent episodes of contractions were re-
treated with parenteral tocolytics unless the cervix
was more than 4 cm dilated or the membranes were
ruptured.
Maternal obstetrical, laboratory, and delivery
data were collected by interview and chart review.
At delivery, the chorioamnion was cultured and
examined histologically as previously described.
2
Infant outcomes were recorded by a combination of
chart review and interview of the mother. Respira-
tory distress syndrome was diagnosed in the pres-
ence of 1) tachypnea and intercostal or substernal
retractions, 2) the need for supplemental inspired
oxygen to maintain arterial oxygen pressure greater
than 50 torr, and 3) bilateral diffuse air broncho-
grams on chest radiograph. Confirmed neonatal
sepsis was diagnosed in the presence of a positive
blood or cerebrospinal fluid culture from the infant
within 3 days of delivery.
Categorical variables were compared using the
chi-square test with Yates correction or two-tailed
Fisher exact test as appropriate. Continuous vari-
ables that were normally distributed were com-
pared using the Student’s t-test. Continuous vari-
ables that were not normally distributed were
compared using a median test.
8 Proportional haz-
ard models developed by Cox were used to compare
the rates (hazard) of preterm delivery among
women receiving antibiotics and those receiving
placebo.
9 For the proportional hazards-model, the
time-to-event was the number of days from enroll-
ment until the patient delivered or reached 35 com-
pleted gestational weeks; the outcome event was
delivery before 35 completed weeks. The rate (the
frequency of outcome events per unit time) of pre-
term delivery was determined by a computer algo-
rithm that includes, at any given time point, only
those women still at risk for preterm delivery. Like-
lihood ratio tests were used to verify the 95% confi-
dence intervals (CI) for the risk ratio. Kaplan-
Meier curves were performed to display the
probability of remaining undelivered for women
receiving antibiotics or placebo.
10
RESULTS
Fifty-six women were enrolled in the study. Thirty
were randomized to receive mezlocillin and eryth-
romycin and 26 were randomized to receive pla-
cebo. Characteristics ofwomen in each ofthe groups
on admission are summarized in Table 1. The
women in the 2 groups did not differ significantly
in any of the characteristics listed in Table 1. Al-
most twice as many women in the antibiotic vs. the
placebo group had C-reactive protein (CRP) levels
above 1.5 mg/dl, the level previously shown to be
elevated in our hospital,
11 but this difference was
not statistically significant. AF cultures were posi-
tive at enrollment in 4 of 21 women randomized to
receive antibiotics and of 15 women randomized
to placebo, but only 64% of women underwent
amniocentesis before randomization.
Results of genital cultures were similar between
the 2 groups. One patient in the antibiotic group
had N. gonorrhoeae and patient in the placebo
group had C. trachomatis in the cervix. Group B
Streptococcus was isolated from 3 (11%) of 28 pa-
tients in the antibiotic group and 2 (8%) of 24 in
the placebo group. E. coli was present in (4%) of
24 patients in the antibiotic group and 0 of 22
patients in the placebo group. No patients in the
antibiotic group and 2 patients in the placebo group
had > 105 bacteria/ml of urine. Vaginal Gram stain
results in the antibiotic group were: normal12
(43%) of 28, intermediate13 (46%), and bacte-
rial vaginosis3 (11%). Vaginal Gram stain re-
sults in the placebo group were: normal12 (46%)
of 26, intermediates9 (35%), and bacterial vagi-
nosis5 (19%).
Women in both groups received similar num-
bers of doses of study medication A summary of
drug dosing and side effects is listed in Table 2.
Antibiotic therapy was well tolerated. Nausea and
vomiting were as common in the placebo group as
the antibiotic group and were likely related to toco-
lytic and other multiple medications used among
women in PTL. The increased diarrhea among
women receiving antibiotics may have been related
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TABLE I. Enrollment characteristics among women randomized to receive mezlocillin/erythromycin or placebo
Mezlocillin/erythromycin Placebo
(n 30) (n 26)
Maternal age, mean _+ SD (years)
Ethnicity: Caucasian
Currently married
Previous preterm birth/total with previous pregnancy >20 weeks
Current smoker
Drug use this pregnancy (excludes alcohol)
Gestational age, mean ___
SD (weeks)
Gestational age, median (weeks)
Bishop’s score, mean ___
SD
Cervical dilatation, mean -+ SD (cm)
Positive amniotic fluid culture
Peripheral WBC count, mean __- SD (I,000/cm3)
Maximum temperature before enrollment, mean --+ SD (C)
CRP, median (mg/dl)
>1.5 mg/dl
Bacterial vaginosis on Gram stain
25.9 4.8 23.9 _+ 5.6 0.20
23 (77%) 19 (73%) 0.76
17 (57%) 14 (54%) 0.95
9/18 (50%) 7/14 (50%) 0.72
12/26 (47%) 10/24 (42%) 0.80
5/27 (19%) 5/24 (21%) 0.99
30. _+ 3. 30. +_ 3.2 0.98
31.0 31.25 0.95
7.0 2.3 6.3 _+ 2.7 0.30
2.1 -+ 1.6 2.1 _+ 1.2 0.95
5/22 (23%) 1/15 (7%) 0.37
12.3 -+ 7. 11.6 -+ 5.5 0.70
36.8 -+ 4.4 36.9 -+ 5.1 0.50
1.75 1.45 0.30
12/19 (63%) 6/16 (38%) 0.20
/8 ( %) s/6 ( 9%) o.so
TABLE 2. Comparison of drug dosing, reason for study drug discontinuation, and side effects between the
randomized treatment groups
a
Mezlocillin/erythromycin (n 30)
IV Oral IV
Placebo (n 26)
Oral
No. doses received, mean -+ SD 11.9 -+ 7.0 15.5 12.3 11.3 -+ 7.4
Stopped drug before course completed 23 19 17
Reason for discontinuation
Delivered 13 12 10
Refused further IV therapy 0 2
Discharged undelivered 6 5
Required other antibodies 0
Experienced side effects
b 3 5 0
Nausea/vomiting 2
Diarrhea 4
Rash
Total with side effects 7 (20%)
16.2 -
12.7
16
2
0
3
3
0
4(%)
aThere are no significant differences in side effects or number of doses between the 2 groups.
bOne patient in each group had more than one side effect.
to either antibiotic. None of the women who devel-
oped diarrhea had a positive stool culture for
Clostridium difficile or a positive C. difficile toxin.
No significantly different rates of adverse effects
related to antibiotics were seen in infants.
Outcome characteristics between the 2 groups in
intent-to-treat analyses are shown in Table 3.
Women receiving antibiotics did not differ from
placebo-treated women in the median gestation at
delivery, median birth weight, or median numbers
of days from enrollment to delivery. Kaplan-Meier
plots of interval from enrollment to delivery are
shown in Figure 1. The hazard ratio for preterm
delivery in the antibiotic compared with the pla-
cebo group is 0.76; 95% CI 0.37-1.5. Women
receiving antibiotics were less likely to develop post-
partum infections or to need antibiotic treatment
during or after labor compared with women in the
placebo group (3/30 vs. 10/26, P 0.03). Posi-
tive membrane cultures were present in 7 (32%) of
22 patients in the antibiotic and 9 (45%) of 20
patients in the placebo group (N.S.). The propor-
tions with histologic chorioamnionitis did not dif-
fer between the 2 treatment groups (Table 3).
Infant outcomes are compared between the 2
treatment groups in Table 3. Gestational age esti-
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TABLE 3. Pregnancy and infant outcome according to treatment group
Mezlocillin/erythromycin
(n 30)
Placebo
(n 26)
Gestational age at delivery (weeks)
Obstetrical dates
Mean -+ SD 33. 4.8
Median 33.8
Dubowitz score
Mean 34.2 5.0
Median 35
Birth weight, mean -+ SD (g) 2,202.4 _
851.3
Birth weight, median (g) 2,360
Median interval from enrollment to delivery (days) 15.5
No. undelivered >1 week 17 (57%)
Maternal non-study antibiotic therapy
Before delivery 3
After delivery
Total 3
Histologic chorioamnionitis 17125 (68%)
Infant hospital days
Median 9
<10 16
10-60 8
>60 5
Infant respiratory distress syndrome 13
Infant antibiotic therapy 14
5-rain Apgar score, mean +- SD 7.4 +- 2.3
33.5 -
4.1 0.8
33 0.9
34.8 -
4. 0.7
34.5 0.9
2,212 862.2 .97
2,280 0.9
15 0.8
3 (50%) 0.8
5 0.4
6 0.04
10 0.03
14/20 (70%) 0.9
12 0.8
II 0.4
II
3
8/25 0.5
9/25 0.6
7.2 +-- 2.8 0.8
aDoes not include one infant who died < day of age.
bChi-square for trend.
mates by Dubowitz and birth weights in the 2
groups were similar. The median hospital stay of
the infant, need for antibiotic or oxygen therapy,
incidence ofrespiratory distress syndrome, and pro-
portion of infants with prolonged hospital stays did
not differ between the 2 groups. Fourteen infants
in the group whose mothers were randomized to
antibiotics received antibiotics during their hospital
stay. One infant was treated with a single dose of
penicillin because of a positive maternal culture for
N. gonorrhoeae at delivery. The remainder received
empiric courses of gentamicin and ampicillin after
admission to the neonatal intensive care unit be-
cause of respiratory distress which could not be
differentiated from pneumonia. One infant in this
group also received later treatment for a positive
culture for coagulase-negative Staphylococcus related
to an IV catheter infection. In the placebo group, 9
infants received empiric courses of antibiotics. In
addition, infant received 2 courses of antibiotic
therapy for coagulase-negative Staphylococcus bacte-
remia related to IV catheter infections. No infants
had complications related to maternal antibiotic
therapy. One infant in each group died. In the
antibiotic group, an infant weighing 1,015 g died
at less than day of age of respiratory insufficiency
related to prematurity. In the placebo group, an
infant weighing 1,096 g at birth died on day 79 of
life of respiratory complications from prematurity.
Because antibiotics were not expected to have an
effect on pregnancies without evidence of infection,
outcomes were compared by therapy among subsets
ofwomen with or without the potential markers of
upper genital tract infection. No difference in preg-
nancy outcome was found between antibiotic and
placebo groups among women with or without bac-
teria in the AF, WBCs in the AF, CRP levels
above 1.5 mg/dl, positive membrane cultures, or
histologic chorioamnionitis (data not shown). In
addition, since positive AF and membrane cul-
tures2’3 are more commonly found in women de-
livering at or below 30 weeks gestation, outcome
by therapy was evaluated in women enrolled at less
than 31 weeks. No difference in outcome with anti-
biotic therapy was found in this subset. Antibiotics
had no influence on the pregnancy outcome of pa-
tients with markers of infection.
Although antibiotics had no effect on the out-
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Fig. I. Probability of remaining undelivered until 35 weeks gestation by randomized treatment
assignment.
comes, even among patient groups at higher risk
for infection, those patients with markers of infec-
tion in either treatment group delivered earlier in
gestation. Patients with compared with those with-
out markers of infection (AF WBCs, AF bacteria,
and CRP > 1.5 mg/dl) had a significantly shorter
interval from enrollment to delivery, a lower gesta-
tional age and birth weight at delivery, and longer
neonatal hospital stays. The magnitude of differ-
ence between those with and without infection or
elevated CRP was large enough to represent sub-
stantial clinical differences. Patients with compared
with those without histologic chorioamnionitis did
not have significantly different outcomes.
DISCUSSION
This study failed to demonstrate any prolongation
of pregnancy among antibiotic-treated compared
with placebo-treated women. Sample size calcula-
tions demonstrate that with the current numbers,
this study has greater than 80% power to detect an
increase in the proportion of women remaining
undelivered for more than week from 50% in the
placebo group to 80% in the antibiotic group or a
doubling of the interval from enrollment to deliv-
ery in the antibiotic group. Thus, it is unlikely that
we have failed to detect a significant benefit in the
antibiotic group.
Previous studies of antibiotic use among women
with PTL with intact membranes have yielded vari-
able results. The previous study most similar to this
study evaluated IV ampicillin and oral erythromy-
cin vs. placebo, and no difference in outcome oc-
curred between the 2 groups.
12 Limited evalua-
tions for possible upper genital tract infection were
done in that study, but the proportion of women
with upper genital tract infection was most likely
low because of a mean 34-day prolongation of preg-
nancy in both groups. This interval was similar to
the mean prolongation of pregnancy in patients in
PTL without AF bacteria in this and 2 previous
studies.
1,3 However, prolongation of pregnancy
was found among women in PTL treated with clin-
damycin compared with placebo, especially among
those presenting before 33 weeks gestation.
14 Pro-
longation of pregnancy also occurred in an un-
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blinded study comparing either oral erythromycin
or oral ampicillin with no therapy among women in
PTL.
is In that study, 24% of patients had cervical
C. trachomatis and 21% of patients had vaginal
group B Streptococcus, rates of infection much
higher than in the present study. Treatment of
these infections may have accounted for the ob-
served effect. Additionally, not all of the outcome
data in that study appeared normally distributed
and more accurate analysis would have been possi-
ble using non-parametric statistics,
is In 2 other
reports, oral erythromycin vs. placebo in addition
to tocolysis given to women in PTL failed to show
any overall prolongation of pregnancy although
some effect was demonstrated in those with cervical
dilatation of at least cm.
6, 7
The lack of benefit of antibiotic therapy may be
related to several factors. First, many patients en-
rolled had no infection and would not be expected
to benefit from antibiotics. Only 14% ofthose tested
had AF infection, and among women not receiving
antibiotics before delivery, only 41% had chorio-
amnion infection and 65% had chorioamnion in-
flammation. Fifty-five percent ofour patients were
above 30 weeks gestation at enrollment, a group
with only an 11% rate of AF infection and a low
rate of membrane infection. 2’3 Thus, the inclusion
ofwomen without upper genital tract infection into
either group would obscure any potential benefit
from antibiotic therapy. Improved tests to identify
women at high risk for both AF and membrane
infection before delivery are needed to allow target-
ing of antibiotic trials to assess better the impact on
upper genital tract infection.
Some women with upper genital tract infection
could have labor that is too advanced at presentation
to be inhibited by the antibiotic-tocolytic therapy
used in this study. Magnesium sulfate and beta-
mimetic agents were the primary tocolytics. Few
patients received prostaglandin synthetase inhibi-
tors. Elevated levels of prostaglandins in the AF
have been found among women in PTL with AF
infection. 8,9 A combination of antibiotics and
prostaglandin synthetase inhibitors might more ef-
fectively inhibit PTL than antibiotic-tocolytic
agents in patients with upper genital tract infection.
However, in one report, pregnancy outcome was
not influenced by a combination of antibiotics and
indomethacin.
2
Antibiotics given may fail to eliminate infection
at a site critical to the stimulation of labor. A criti-
cal site could be the decidua
18 and this area was not
sampled after antibiotic therapy in this study, al-
though the rate of positive chorioamnion cultures
did not differ between the 2 groups. Antibiotic
levels in the decidua and chorioamnion may not be
adequate to treat an established infection or may
enhance the effects of infection on inciting PTL.
Cytokines are released in response to AF infec-
tion
18,19 and histologic chorioamnionitis,
19 pre-
sumably stimulated by bacterial products. Lysis of
bacteria cell walls by antibiotics and release of li-
popolysaccharide might even aggravate PTL by
further stimulating the cytokine response. Success-
ful attempts to inhibit infected patients in PTL may
require the down regulation of the cytokine re-
sponse before antibiotic therapy by the use of corti-
costeroids or cytokine antagonists.
2
It was apparent that the markers evaluated (AF-
WBC’s, AF bacteria, CRP > 1.5 Ig/dl) identify
patients at significant risk for delivery at a low
gestational age and for prolonged infant hospital-
ization. These markers identify a high-risk group
with either infection, inflammation, or some other
unidentified upper genital tract condition. Thus,
despite the failure of antibiotics to prolong the ges-
tation of patients in PTL, we reject the notion that
infection is not related to preterm delivery. Further
studies are necessary to prove a causal relationship
between the two, and should be directed at the use
of rapid tests to detect AF and chorioamnion infec-
tion and the evaluation of antibiotic therapy in com-
bination with other therapies such as prostaglandin
synthetase inhibitors and cytokine antagonists. In
addition, studies are needed to evaluate whether
women at increased risk of preterm delivery with
upper genital tract infection can be identified and
treated earlier in pregnancy to prevent PTL.
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